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Establishing the Prognostic Value of
Rb-82 PET Myocardial Perfusion Imaging
A Step in the Right Direction*
Raymond. J. Gibbons, MD, Panithaya Chareonthaitawee, MD
Rochester, MinnesotaIn the last decade, positron emission tomography
(PET) myocardial perfusion imaging (MPI) has
emerged as a valuable clinical tool for the manage-
ment of patients with known or suspected coronary
artery disease (CAD). Compared with single-
photon emission computed-tomography (SPECT),
PET provides higher-quality images and superior
diagnostic accuracy (1). Increased availability of
PET scanners, Medicare approval of PET-MPI
reimbursement, and greater access to the generator-
produced perfusion tracer rubidium (Rb)-82 have
See page 846
increased utilization. However, despite the growth
of Rb-82 PET-MPI, the literature showing its
prognostic value has been limited (2–6). Small
sample sizes (2,3), possible overlap in study popu-
lations (3,4), a focus on high-risk patients with
known CAD (2), substantial patient exclusions
(2–4,6), limited outcomes data (5), and smaller
numbers of cardiac events (3) are some limitations
of the existing literature. Furthermore, the majority
of studies did not use current PET technology,
which may include the application of computed
tomography (CT) for attenuation correction (AC)
and electrocardiographic (ECG) gating for mea-
surement of left ventricular (LV) volumes and
systolic function (LVEF).
In this issue of iJACC, Dorbala et al. (7) report
on the prognostic value of gated Rb-82 PET-MPI
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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Minnesota. Dr. Gibbons has received a research grant from King
Pharmaceuticals for development of an adenosine agonist.in 1,432 consecutive patients followed up for a
mean of 1.7 years. The investigators carefully per-
formed image acquisition, processing, and interpre-
tation using contemporary, clinically relevant tech-
niques, including CT AC, rest/stress ECG gating,
and iterative reconstruction (7). In their study, the
rates of both all-cause death and cardiac events
increased with increasing extent and severity of
Rb-82 PET-MPI findings. In Cox proportional
hazards modeling, Rb-82 PET-MPI variables of
ischemia and scar and the difference between LVEF
at rest and stress (LVEF reserve) were found to be
incremental to clinical variables and LVEF at rest
for predicting both cardiac events and all-cause
death. In addition, LVEF reserve had incremental
prognostic value compared with perfusion image
interpretation—a truly novel finding.
What are the potential weaknesses of this
study? The study group is quite heterogeneous—
31% had known CAD, 17% were studied for
pre-operative evaluation, 48% had an intermedi-
ate likelihood of CAD. Both rest and stress
LVEF were only available on 985 patients (69%
of the study group); these patients were not
formally compared with the remaining patients.
The clinical models for cardiac events and all-
cause mortality only included those variables that
were statistically significant in the study group.
However, experienced clinicians usually also in-
corporate the presence and severity of typical
angina and diabetes not requiring insulin into
their patient assessment; these variables should
therefore be forced into prognostic models to
better reflect clinical decision making. The an-
nual all-cause mortality rate was high (3.5%) in
patients with normal perfusion scans, suggesting
a population with extensive noncardiac problems.
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856On balance, we consider these weaknesses minor;
his article makes a substantial contribution to the
rognostic literature regarding Rb-82 PET-MPI.
hould it inspire widespread use of LVEF reserve
nd broad application of PET-MPI? This seems
remature. The recently published negative multi-
enter experience with echocardiographic parame-
ers for predicting the outcome of cardiac resyn-
hronization therapy underscores the importance of
dequate multicenter validation before widespread
linical application of new imaging techniques (8).
his is particularly important for PET, because it is
nder scrutiny (along with cardiac magnetic reso-
ance and CT) because its (primarily noncardiac)
tilization has increased dramatically in the past 10
ears. Before LVEF reserve is used on a more
idespread basis, its potential benefit must be
urther evaluated and compared with its cost/
nconvenience. Most of the investigators’ patients
nderwent dipyridamole stress, which requires
ore prolonged monitoring, and therefore more
urse/physician time, than adenosine stress. Al-
hough a small minority of their patients underwent
denosine stress, we are not certain that their results
an be extrapolated to adenosine because its shorter
alf-life is likely to lead to less prolonged ischemia
nd more rapid LVEF recovery than dipyridamole.
he investigators’ receiver-operator characteristic
urve analysis is statistically rigorous, but the clin-
cal impact of such receiver-operator characteristic
urve differences may be surprisingly modest (9).
deally, one should demonstrate how many patients
re reclassified, that is, how many patients are
oved across thresholds that prompt a change in
linical management. The investigators’ heteroge-
eous study group makes such an analysis very
hallenging. As mentioned, 31% of the investiga-
ors’ patients had known CAD. The complex clin-
cal decision making in such patients depends on
heir symptoms and their time since revasculariza-
ion/myocardial infarction. An additional 17% of
atients were studied as part of a pre-operative
Annual Event Rates in Relation to Rb-82 PET-MPI Results
n Known CAD (%)
All-Cause Death (%)
Normal
Mildly
Abnormal
Moderately
Abnormal
657 50* 0.8 2.5 5.8
367 40 NA NA NA
1,441 54 2.4 4.1
1,432 31 2.5 5.0 8.0
n: 48%, prior revascularization: 37%, and on medical therapy: 50%.
isease; NA  not applicable; PET-MPI  positron emission tomography–myocardial pvaluation. Current clinical practice guidelines are
ar more restrictive regarding such pre-operative
esting (10). Many of the investigators’ patients
ere probably tested before publication of the latest
ational guidelines and might not merit testing in
he current era. Thus, the clinical decision-making
rocess in these 2 groups is likely much different
han in patients with an intermediate likelihood of
AD, the largest group in this study.
How do the results of the current study compare
ith the existing literature on the prognostic value
f PET-MPI? Overall, there is general agreement
n the prognostic value of Rb-82 PET-MPI among
tudies. However, mortality and cardiac event rates
ary widely (Table 1), likely reflecting the hetero-
eneous populations across studies (selection bias)
nd other methodological factors. The disparity in
ardiac event rates among studies may be attributed
o the profound susceptibility of this approach to
isclassification bias (11). Variability in censoring
elated to revascularization (12) and uncertainty
egarding the number of patients revascularized
fter Rb-82 PET-MPI can also contribute to the
isparity. Finally, unlike SPECT-MPI, PET-MPI
tudies are characterized by less standardization in
he reporting of imaging variables. PET-MPI stud-
es have used different criteria for defining normal
ersus abnormal results; for classifying mild, mod-
rate, and severe abnormalities; and for describing
schemia and scar (2,3,6,7).
What can an evidence-based physician conclude
rom this study? The incremental value of Rb-82
ET perfusion and function shown in the current
tudy, combined with its previously reported higher
iagnostic accuracy (1), interpretative certainty (1),
ower patient radiation exposure (13), and similar
edicare charges in many parts of the U.S. com-
ared with SPECT, support more widespread use
f PET for patients in whom it has a clear advan-
age. Within our institution, we recommend it for
en over 120 kg and women over 100 kg, in whom
PECT images are frequently of poor quality. We
Cardiac Events (%)
Severely
Abnormal Normal
Mildly
Abnormal
Moderately
Abnormal
Severely
Abnormal
5.7 3.2 4.3 7.0 5.6
NA 0.4 2.3 7.0
6.9 NA NA NA NA
10.0 0.5 2.5 5.5 10.0Table 1. Approximate
Author (Ref #)
Marwick et al. (2)
Yoshinaga et al. (3)
Lertsburapa et al. (6)
Dorbala et al. (7)
*Prior myocardial infarctio
erfusion imaging; Rb  rubidium.
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857elieve that broader application of PET to other
atients is not yet justified, because SPECT-MPI
as a far larger and more robust prognostic database
ncompassing at least 40,000 patients in over 20
tudies (14). To match these considerable data,
arefully designed outcomes-based single-center
tudies and multicenter registries, such as theaging in patients with known or sus- diol 2007;50:1707–AD) trial, are needed. Such studies should help
dentify those patients who are most likely to
enefit from PET-MPI and thereby justify more
idespread use.
eprint requests and correspondence: Dr. Raymond J.
ibbons, Mayo Clinic, 200 First Street SW, Rochester,PARC (Study of Perfusion and Anatomy’s Role in Minnesota 55905. E-mail: gibbons.raymond@mayo.edu.1
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